Loading news...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.
Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Partners.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Fourth Quarter Revenue: $994.2 million, a 2.6% decline on an organic basis.Full Year Revenue: $4.02 billion, with an organic revenue decrease of 1.6%.Operating
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories Q4 Review: Approaching A Bottom
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services from biotech clients.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.
Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL
Besides Wall Street's top-and-bottom-line estimates for Charles River (CRL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
CRL heads into Q4 earnings with collaborations and strength in RMS and Manufacturing, even as DSA headwinds weigh on revenue expectations.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.